Most medical devices in the United States come to market with limited clinical data, and device surveillance is viewed as a ...

Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital ...

Rajesh Menon said, “We are pleased to appoint Zeal Global Corp as our new General Sales Agent for our cargo operations in ...

Ah, the tangled web of history—where the guy who helped bring us leaded gasoline also played a role in cancer research. Meanwhile, neuroscientists confirm what we all suspected: our brains love a good ...

Dave Weldon was scheduled to have a confirmation hearing on Thursday, but the White House scrapped the nomination of the ...

LEO Pharma A/S, a global leader in medical dermatology, today presented late-breaking data showcasing responses in a subgroup of patients from the DELTA 1 and 2 trials at the 83 rd American Academy of ...

Roquefort also on Monday said CEO Reginald has announced his intention to resign, alongside Non-Executive Director Martin Evans. Both resignations will become effective at the market close on March 17 ...

Nevertheless, Manchester’s life sciences cluster has bounced back and evolved following AstraZeneca’s departure, Sheppard ...

The company is planning a Phase 3 trial for the new formulation of lenacapavir, Stat reports. Other pharma and technology news is on microplastics and the spread of antibiotic-resistant superbugs; a ...

Prior to 60 Minutes' March 9, 2025 broadcast, which featured correspondent Cecilia Vega's report on the Purdue Pharma bankruptcy case, we reached out to Purdue Pharma for comment on our story ...

aTyr Pharma (NASDAQ: ATYR), with a market capitalization of $336 million, reported its fourth-quarter 2024 earnings, posting a smaller-than-expected loss and demonstrating significant progress in ...

In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Inozyme Pharma (INZY – Research Report). The company’s shares opened today at $1.14. Effectively assess a stock ...